POM-VPS Prescription Required

Bravoxin Suspension for Injection for Cattle and Sheep

Active ingredients: Clostridium chauvoei, Clostridium haemolyticum, Clostridium novyi, Clostridium perfringens, Clostridium septicum, Clostridium sordellii, Clostridium tetani

Form

Injection

Species

Cattle Sheep

Manufacturer

Intervet International B.V.

VMD MA No.

06376/3031

What it's used for

perfringens type C, C. perfringens type D, Clostridium chauvoei, type B, Clostridium septicum, Clostridium sordelliiClostridium haemolyticum and against te...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clostridium chauvoei + Clost...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bravoxin Suspension for Injection for Cattle and Sheep — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

perfringens type C, C. perfringens type D, Clostridium chauvoei,
type B, Clostridium septicum, Clostridium sordelliiClostridium haemolyticum and
against tetanus caused by Clostridium tetani.
For the passive immunisation of lambs and calves against infections caused by the
above mentioned clostridial species (except C. haemolyticum in sheep).
Onset of immunity:
Sheep and Cattle: 2 weeks after the basic vaccination course (as demonstrated by
serology only).
Duration of active immunity:
As demonstrated by serology only:
Sheep: 1 year against type B, C. sordellii,
C. Tetani;
< 6 months against ,
Cattle: 1 year against C. perfringens type D;
< 1 year against type A, B and C;
< 6 months against type B, C. septicum, C. sordellii,
C. chauvoei.
An anamnestic humoral immune response (immunological memory) to all
components was demonstrated 1 year following the basic course of vaccination.
Duration of passive immunity:
As demonstrated by serology only:
Lambs: At least 2 weeks for C. septicum and C. chauvoei;
At least 8 weeks for C. perfringens type B and C. perfringens type C;
At least 12 weeks for C. perfringens type A, type D, C. novyi
type B, C. tetani and C. sordellii;
No passive immunity was observed for C. haemolyticum.
Calves: At least 2 weeks for C. sordellii C. haemolyticum;
At least 8 weeks for C. septicum and ;
At least 12 weeks for C. perfringens type A, type B, C.
perfringens type C, C. type D, C. novyi type B, and C. tetani.

Dose:
- Sheep: 1 ml – from 2 weeks of age
- Cattle: 2 ml – from 2 weeks of age
Administration:
By subcutaneous injection preferably in the loose skin on the side of the neck,
observing aseptic precautions.
Shake the bottle thoroughly before use.
Syringes and needles should be sterile before use and the injection should be made
through an area of clean, dry skin taking precautions against contamination.
Basic vaccination:
section 3.2 and 3.4).
Re-vaccination:
intervals after the basic vaccination (see section 3.2.)
Use in pregnancy:
To provide passive protection of the offspring, via the colostrum, a single re-
vaccination should be administered between 8 and 2 weeks before parturition,
provided that animals have received a full basic vaccination course before
pregnancy.

Do not use in sick or immunodeficient animals.

Cattle and sheep:
Very common
(>1 animal / 10 animals treated):
Injection site swelling
.Common
(1 to 10 animals / 100 animals treated):
Injection site abscess, injection site
skin discolouration
.
Hyperthermia
.
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Injection site pain
.Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Anaphylactic type reaction
.
Up to a mean value of 6 cm in sheep and 15 cm diameter in cattle; sometimes
reactions of up to 25 cm diameter may be seen in cattle. Most local reactions resolve
within 3-6 weeks in sheep and in less than 10 weeks in cattle. In a minority of
animals they may persist longer.
Returns to normal as the local reaction resolves.
Mild.
For 1-2 days post first vaccination.
In such cases appropriate treatment such as adrenaline should be administered
without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Vaccinate healthy animals only.
The effectiveness of the vaccine in providing passive immunity to young lambs and
calves depends on these animals ingesting adequate amounts of colostrum on the
first day of life.
Clinical trials have demonstrated that the presence of maternal derived antibodies
(MDA), particularly against C. tetani, C. novyi type B, C. perfringens type A (calves
only), C. chauvoei (lambs only) and C. perfringens type D may reduce the antibody
response to vaccination in young lambs and calves. Therefore, to ensure an optimal
response in young animals with high levels of MDA, the basic vaccination should be
delayed until the levels wane (which is after about 8-12 weeks of age, see section
3.2).

Special precautions for safe use in the target species:
It is good practice to observe animals regularly for adverse reactions at the injection
site following vaccination. It is recommended to seek medical advice from a
veterinarian in case of a severe injection site reaction.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 °C – 8 °C). Do not freeze.
Protect from light.

Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.